Compare Stocks: DYAI, ADCT, IFRX, and EQ

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADCT ADC Therapeutics	$1.05 -15.0%	$1.15	$0.78 ▼ $4.98	$132.91M	1.89	1.26 million shs	2.06 million shs
DYAI Dyadic International	$0.78 -11.5%	$0.97	$0.65 ▼ $1.60	$28.39M	1.12	182,264 shs	315,988 shs
EQ Equillium	$2.00 -8.5%	$2.69	$0.76 ▼ $3.54	$126.14M	1.82	630,873 shs	458,794 shs
IFRX InflaRx	$2.02 +0.2%	$1.88	$0.78 ▼ $2.95	$145.66M	2.48	1.16 million shs	998,444 shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADCT ADC Therapeutics	+1.69%	+12.09%	-2.74%	-64.30%	-58.94%
DYAI Dyadic International	-16.19%	-9.23%	-13.73%	+27.54%	+3.53%
EQ Equillium	-2.24%	-0.46%	-24.31%	-15.83%	+133.38%
IFRX InflaRx	+0.50%	+13.56%	-2.43%	-15.55%	+141.30%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADCT ADC Therapeutics	$1.05 -15.0%	$1.15	$0.78 ▼ $4.98	$132.91M	1.89	1.26 million shs	2.06 million shs
DYAI Dyadic International	$0.78 -11.5%	$0.97	$0.65 ▼ $1.60	$28.39M	1.12	182,264 shs	315,988 shs
EQ Equillium	$2.00 -8.5%	$2.69	$0.76 ▼ $3.54	$126.14M	1.82	630,873 shs	458,794 shs
IFRX InflaRx	$2.02 +0.2%	$1.88	$0.78 ▼ $2.95	$145.66M	2.48	1.16 million shs	998,444 shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADCT ADC Therapeutics	+1.69%	+12.09%	-2.74%	-64.30%	-58.94%
DYAI Dyadic International	-16.19%	-9.23%	-13.73%	+27.54%	+3.53%
EQ Equillium	-2.24%	-0.46%	-24.31%	-15.83%	+133.38%
IFRX InflaRx	+0.50%	+13.56%	-2.43%	-15.55%	+141.30%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADCT ADC Therapeutics	2.33	Hold	$6.25	509.76% Upside
DYAI Dyadic International	2.33	Hold	$3.00	269.00% Upside
EQ Equillium	2.91	Moderate Buy	$7.57	247.31% Upside
IFRX InflaRx	2.88	Moderate Buy	$7.33	263.94% Upside

Current Analyst Ratings Breakdown

Latest DYAI, ADCT, IFRX, and EQ Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/11/2026	EQ Equillium	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
8/7/2026	IFRX InflaRx	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$4.00 ➝ $6.00
7/27/2026	IFRX InflaRx	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
7/21/2026	EQ Equillium	Clear Str Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
7/17/2026	ADCT ADC Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/13/2026	EQ Equillium	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight
7/13/2026	EQ Equillium	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell
6/24/2026	DYAI Dyadic International	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
6/24/2026	EQ Equillium	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
6/24/2026	IFRX InflaRx	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
6/8/2026	ADCT ADC Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Neutral

(Data available from 8/13/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADCT ADC Therapeutics	$81.36M	1.60	N/A	N/A	($1.50) per share	-0.68
DYAI Dyadic International	$1.67M	17.71	N/A	N/A	$0.03 per share	27.10
EQ Equillium	$41.10M	3.35	N/A	N/A	$0.47 per share	4.64
IFRX InflaRx	$30K	4,855.48	N/A	N/A	$2.35 per share	0.86

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADCT ADC Therapeutics	-$142.62M	-$1.05	N/A	N/A	N/A	-173.02%	N/A	-44.70%	8/13/2026 (Estimated)
DYAI Dyadic International	-$7.36M	-$0.23	N/A	N/A	N/A	-192.40%	-1,005.45%	-77.64%	N/A
EQ Equillium	-$22.40M	-$0.32	N/A	N/A	N/A	N/A	-61.43%	-53.72%	8/13/2026 (Estimated)
IFRX InflaRx	-$51.63M	-$0.58	N/A	N/A	N/A	N/A	-53.56%	-43.02%	N/A

Latest DYAI, ADCT, IFRX, and EQ Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	ADCT ADC Therapeutics	-$0.2160	-$0.11	+$0.1060	-$0.11	$18.89 million	$19.25 million
8/13/2026	Q2 2026	EQ Equillium	-$0.0540	N/A	N/A	N/A	N/A	N/A
8/12/2026	Q2 2026	DYAI Dyadic International	-$0.0350	-$0.06	-$0.0250	-$0.06	$1.03 million	$0.96 million
8/6/2026	Q2 2026	IFRX InflaRx	-$0.0666	-$0.11	-$0.0434	-$0.10	$0.01 million	N/A
5/13/2026	Q1 2026	DYAI Dyadic International	-$0.04	-$0.05	-$0.01	-$0.05	$0.90 million	$1.11 million
5/13/2026	Q1 2026	EQ Equillium	-$0.04	-$0.06	-$0.02	-$0.06	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADCT ADC Therapeutics	N/A	N/A	N/A	N/A	N/A
DYAI Dyadic International	N/A	N/A	N/A	N/A	N/A
EQ Equillium	N/A	N/A	N/A	N/A	N/A
IFRX InflaRx	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADCT ADC Therapeutics	N/A	4.09	4.02
DYAI Dyadic International	4.08	2.42	2.42
EQ Equillium	N/A	18.62	18.62
IFRX InflaRx	N/A	8.22	8.22

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADCT ADC Therapeutics	41.10%
DYAI Dyadic International	27.95%
EQ Equillium	27.05%
IFRX InflaRx	42.39%

Insider Ownership

Company	Insider Ownership
ADCT ADC Therapeutics	5.10%
DYAI Dyadic International	20.90%
EQ Equillium	17.84%
IFRX InflaRx	16.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADCT ADC Therapeutics	310	127.19 million	120.70 million	Optionable
DYAI Dyadic International	7	36.44 million	28.82 million	Optionable
EQ Equillium	40	63.23 million	51.95 million	Not Optionable
IFRX InflaRx	60	72.29 million	60.51 million	Optionable

DYAI, ADCT, IFRX, and EQ Headlines

Recent News About These Companies

InflaRx N.V.

August 11 at 12:51 AM | marketwatch.com

InflaRx (NASDAQ:IFRX) Price Target Raised to $6.00

August 10 at 2:24 AM | americanbankingnews.com

What is HC Wainwright's Estimate for InflaRx Q3 Earnings?

August 10 at 1:12 AM | americanbankingnews.com

HC Wainwright Estimates InflaRx's Q3 Earnings (NASDAQ:IFRX)

August 10 at 1:12 AM | marketbeat.com

InflaRx (NASDAQ:IFRX) Announces Quarterly Earnings Results, Misses Estimates By $0.04 EPS

August 7, 2026 | marketbeat.com

Cantor Fitzgerald Increases InflaRx (NASDAQ:IFRX) Price Target to $6.00

August 7, 2026 | marketbeat.com

InflaRx Files Mid‑Year 2026 Unaudited Results in SEC Form 6‑K

August 6, 2026 | tipranks.com

InflaRx Reports Q2 2026 Results and Business Update, Advances Izicopan in AAV and Renal Diseases

August 6, 2026 | quiverquant.comQ

InflaRx Reports Second Quarter 2026 Results and Highlights Key Achievements and Expected Milestones

August 6, 2026 | globenewswire.com

InflaRx N.V. (NASDAQ:IFRX) Receives Consensus Rating of "Moderate Buy" from Analysts

July 30, 2026 | marketbeat.com

InflaRx to Report Second Quarter 2026 Results on August 6, 2026

July 30, 2026 | globenewswire.com

InflaRx (IFRX) to Announce Earnings on Thursday

July 30, 2026 | marketbeat.com

Analysts Offer Insights on Healthcare Companies: InflaRx (IFRX) and Baxter International (BAX)

July 29, 2026 | theglobeandmail.com

InflaRx (NASDAQ:IFRX) Upgraded by Zacks Research to "Strong-Buy" Rating

July 29, 2026 | marketbeat.com

InflaRx (NASDAQ:IFRX) Trading Down 2.3% - Time to Sell?

July 27, 2026 | marketbeat.com

InflaRx (IFRX) Gets a Buy from Oppenheimer

July 18, 2026 | theglobeandmail.com

InflaRx Assessing Feasibility of Broadened Strategy for ANCA‑Associated Vasculitis in Europe ...

June 30, 2026 | caledonianrecord.comC

InflaRx Assessing Feasibility of Broadened Strategy for ANCA‑Associated Vasculitis in Europe Following EMA Recommendation on Tavneos

June 30, 2026 | globenewswire.com

What Do Analysts Say About InflaRx N.V. (IFRX)?

June 10, 2026 | insidermonkey.com

Here’s Why InflaRx (IFRX) is Among the 10 Most Volatile Penny Stocks to Buy Now

May 31, 2026 | insidermonkey.com

Raymond James upgrades InflaRx NV (IFRX)

May 14, 2026 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

DYAI, ADCT, IFRX, and EQ Company Descriptions

ADC Therapeutics NYSE:ADCT

$1.04 -0.19 (-15.04%)

Closing price 03:59 PM Eastern

Extended Trading

$1.04 0.00 (0.00%)

As of 04:06 PM Eastern

ADC Therapeutics SA focuses on advancing its proprietary antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product is ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The company is also seeking to continue expanding ZYNLONTA into international markets and into earlier lines of DLBCL and indolent lymphomas, including follicular lymphoma (FL) and marginal zone lymphoma (MZL) as a single agent and in combination through its LOTIS-5 confirmatory Phase 3 clinical trial and LOTIS-7 Phase 1b clinical trial, as well as through investigator-initiated trials (IITs). In addition, it is investigating a CD-22 targeted compound, ADCT-602 that is in a Phase 1/2 investigator-initiated study in relapsed or refractory B-cell acute lymphoblastic leukemia. Further, its clinical-stage pipeline consists of ADCT-601 (mipasetamab uzoptirine) targeting AXL as a single agent and/or in combination in sarcoma, pancreatic, and NSCLC, as well as pre-clinical stage pipeline includes a portfolio of next generation investigational ADCs targeting Claudin-6, NaPi2b, PSMA, and other undisclosed targets. The company was incorporated in 2011 and is headquartered in Epalinges, Switzerland.

Dyadic International NASDAQ:DYAI

$0.78 -0.10 (-11.48%)

Closing price 03:59 PM Eastern

Extended Trading

$0.80 +0.02 (+2.82%)

As of 04:09 PM Eastern

Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States and internationally. It utilizes C1-cell protein production platform based on an industrially proven microorganism (C1) for the development and production of biologic products including enzymes and other proteins for human and animal health. The company offers DYAI-100, SARS-CoV-2-RBD antigen vaccine candidate towards a first-in-human Phase 1 clinical trial to demonstrate the safety in humans of a protein produced using the C1 platform. It has also developed the Dapibus thermophilic, a filamentous fungal-based microbial protein production platform to enable the development and large-scale manufacture of cost-effective proteins, metabolites, and other biologic products for use in non-pharmaceutical applications, including food, nutrition, and wellness. The company has a research and development agreement with VTT Technical Research Centre of Finland, Ltd.; license agreement with South Africa's Rubic One Health; Joint Development Agreement with a Global Food Ingredient Company; and sub-license agreement with Abic Biological Laboratories Ltd., Alphazyme, LLC, and Abic Biological Laboratories Ltd. Dyadic International, Inc. was founded in 1979 and is headquartered in Jupiter, Florida.

Equillium NASDAQ:EQ

$2.00 -0.19 (-8.49%)

Closing price 03:59 PM Eastern

Extended Trading

$2.06 +0.06 (+3.21%)

As of 04:07 PM Eastern

Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis. It also develops EQ101 completed phase 1/2 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ302 to treat gastrointestinal indications. In addition, it serves dermatology, gastroenterology, rheumatology, hematology, transplant science, oncology, and pulmonology area. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.

InflaRx NASDAQ:IFRX

$2.02 +0.01 (+0.25%)

Closing price 03:59 PM Eastern

Extended Trading

$2.02 0.00 (0.00%)

As of 04:04 PM Eastern

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company develops INF904, an oral, small molecule drug candidate for the chronic inflammatory and autoimmune diseases; IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases; and Gohibic (vilobelimab) for the treatment of COVID-19 and broader ARDS. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest DYAI, ADCT, IFRX, and EQ Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest DYAI, ADCT, IFRX, and EQ Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

DYAI, ADCT, IFRX, and EQ Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

DYAI, ADCT, IFRX, and EQ Company Descriptions

ADC Therapeutics NYSE:ADCT

Dyadic International NASDAQ:DYAI

Equillium NASDAQ:EQ

InflaRx NASDAQ:IFRX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest DYAI, ADCT, IFRX, and EQ Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest DYAI, ADCT, IFRX, and EQ Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

DYAI, ADCT, IFRX, and EQ Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

DYAI, ADCT, IFRX, and EQ Company Descriptions

ADC Therapeutics NYSE:ADCT

Dyadic International NASDAQ:DYAI

Equillium NASDAQ:EQ

InflaRx NASDAQ:IFRX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools